All In Biotech

Drug Trial Radar · NCT02622321

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors

A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Patients With Inhibitors

Last checked: Nov 19, 2026Latest source record: Jun 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 113 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

113

Actual

Start

Nov 18, 2015

Primary completion

Oct 25, 2016

Study completion Dec 1, 2020

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Chugai Pharmaceutical
First posted
Dec 4, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, open-label study will evaluate the safety, efficacy and pharmacokinetics of prophylactic emicizumab treatment in participants previously treated with episodic or prophylactic bypassing agents. Episodic bypassing agent participants will be randomized in a 2:1 fashion to receive emicizumab prophylaxis (Arm A) versus no prophylaxis (Arm B) and will be stratified across Arms A and B according to the number of bleeds they experienced over the last 24 weeks prior to study entry (less than \[\<\] 9 or greater than or equal to \[\>/=\] 9 bleeds); Arm B participants will have the opportunity to switch to emicizumab prophylaxis after at least 24 weeks on-study. Prophylactic bypassing agent participants will switch to emicizumab prophylaxis (Arm C) from the start of the trial; enrollment will be extended for 24 weeks after the last participant has enrolled in Arms A or B or until approximately 50 participants have enrolled in Arm C, whichever occurs first. Episodic bypassing agent participants who previously participated in the non-interventional study BH29768 (NCT02476942) who were unable to enroll in Arms A or B, or participants on prophylactic bypassing agents who were unable to enroll in Arm C, prior to their closure will have the opportunity to enroll in Arm D. Like participants in Arms A and C, Arm D participants will receive emicizumab prophylaxis from the start of the trial. All participants will continue to receive episodic bypassing agent therapy to treat breakthrough bleeds, preferably with recombinant activated factor VII (rFVIIa).

Conditions

  • Hemophilia A

Interventions

  • EmicizumabDrug

    Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.

  • rFVIIaDrug

    Participants will continue to receive rFVIIa.

  • aPCCDrug

    Participants will continue to receive aPCC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds, Arm A: Emicizumab Versus Arm B: No ProphylaxisTime frame: From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)

Locations

44 sites in 14 countries. Site status is shown where the registry gives one.

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Santa Monica Oncology Center

    Santa Monica, California

  • University of Colorado Denver, Children's Hospital

    Aurora, Colorado

  • Winship Cancer Institute

    Atlanta, Georgia

  • Boston Childrens Hospital

    Boston, Massachusetts

  • Children's Hospital of Michigan; Pediatrics

    Detroit, Michigan

  • Cornell Univ Medical College; Hematology-Oncolog

    New York, New York

  • Oregon Health & Science Uni ; Dept of Pediatrics

    Portland, Oregon

  • Pennsylvania State Hershey Medical Center; Division of Hematology/Oncology, H046

    Hershey, Pennsylvania

  • Univ of TX Health Science Ctr; Gulf States Hemo and Throm Ctr

    Houston, Texas

  • Bloodworks Northwest (formerly Puget Sound Blood Center); Hemophilia

    Seattle, Washington

  • Royal Prince Alfred Hospital; Haematology

    Camperdown, New South Wales, Australia

  • The Alfred Hospital, Melbourne; Thrombosis and Haemostasis Unit

    Melbourne, Victoria, Australia

  • ICIC

    San José, Costa Rica

  • Hopital Cardio-vasculaire Louis Pradel; Hemostase clinique

    Bron, France

  • CH de Bicetre; Centre de Traitement d' Hemophilie

    Le Kremlin-Bicêtre, France

  • Hopital Cardiologique; Hematologie B

    Lille, France

  • Groupe Hospitalier Necker Enfants Malades

    Paris, France

  • Universitätsklinikum Bonn; Institut für Experimentelle Hämatologie und Transfusionsmedizin

    Bonn, Germany

  • CTC North GmbH & Co. KG am Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • Hämophilie-Zentrum Rhein Main GmbH

    Mörfelden-Walldorf, Germany

  • IRCCS Ca' Granda Ospedale Maggiore Policlinico; Centro Emofilia e Trombosi "Angelo Bianchi e Bonomi"

    Milan, Lombardy, Italy

  • AOU Careggi; SOD Malattie Emorragiche

    Florence, Tuscany, Italy

  • Nagoya University Hospital

    Aichi, Japan

  • Hiroshima University Hospital

    Hiroshima, Japan

  • Hyogo College of Medicine Hospital

    Hyōgo, Japan

  • St. Marianna University School of Medicine Hospital

    Kanagawa, Japan

  • Hospital of the University of Occupational and Environmental Health,Japan

    Kitakyushu-shi, Japan

  • Nara Medical University Hospital

    Nara, Japan

  • Tokyo Medical University Hospital

    Tokyo, Japan

  • Auckland City Hospital; Auckland Haemophilia Centre

    Auckland, New Zealand

  • Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii

    Gdansk, Poland

  • SPSK Nr1 Klinika Hematoo&Transpl.Szpiku

    Lublin, Poland

  • ALVAMED Lekarskie Gabinety Specjalistyczne

    Poznan, Poland

  • Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych

    Warsaw, Poland

  • Charlotte Maxeke Johannesburg Hospital; Haemophilia Comprehensive Care Center

    Johannesburg, South Africa

  • Severance Hospital

    Seoul, South Korea

  • Hospital Universitario la Paz; Servicio de Hematologia

    Madrid, Spain

  • Hospital Universitario Virgen del Rocio; Servicio de Hematologia

    Seville, Spain

  • Hospital Universitario la Fe; Servicio de Hematologia

    Valencia, Spain

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.